258 related articles for article (PubMed ID: 38069345)
1. Early-Onset Ovarian Cancer <30 Years: What Do We Know about Its Genetic Predisposition?
Horackova K; Janatova M; Kleiblova P; Kleibl Z; Soukupova J
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069345
[TBL] [Abstract][Full Text] [Related]
2. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes:
Hanson H; Kulkarni A; Loong L; Kavanaugh G; Torr B; Allen S; Ahmed M; Antoniou AC; Cleaver R; Dabir T; Evans DG; Golightly E; Jewell R; Kohut K; Manchanda R; Murray A; Murray J; Ong KR; Rosenthal AN; Woodward ER; Eccles DM; Turnbull C; Tischkowitz M; ; Lalloo F
J Med Genet; 2023 May; 60(5):417-429. PubMed ID: 36411032
[TBL] [Abstract][Full Text] [Related]
3. Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic
Alenezi WM; Fierheller CT; Revil T; Serruya C; Mes-Masson AM; Foulkes WD; Provencher D; El Haffaf Z; Ragoussis J; Tonin PN
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456503
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
[TBL] [Abstract][Full Text] [Related]
5. [BRCA2 Mutation Profile in a Proband with Hereditary Breast and Ovarian Cancer-Two Germline Pathogenic Variants Aligned in the Cis Position].
Yukisawa S; Kakinuma T; Yotsumoto J; Kawakami K; Furukawa J; Shinozaki H
Gan To Kagaku Ryoho; 2023 Oct; 50(10):1089-1091. PubMed ID: 38035841
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
7. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P
PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125
[TBL] [Abstract][Full Text] [Related]
8. Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes.
Zhu Q; Zhang J; Chen Y; Hu Q; Shen H; Huang RY; Liu Q; Kaur J; Long M; Battaglia S; Eng KH; Lele SB; Zsiros E; Villella J; Lugade A; Yao S; Liu S; Moysich K; Odunsi KO
Int J Cancer; 2020 Apr; 146(8):2147-2155. PubMed ID: 31265121
[TBL] [Abstract][Full Text] [Related]
9. The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
Witjes VM; Ligtenberg MJL; Vos JR; Braspenning JCC; Ausems MGEM; Mourits MJE; de Hullu JA; Adang EMM; Hoogerbrugge N
Gynecol Oncol; 2023 Jul; 174():121-128. PubMed ID: 37182432
[TBL] [Abstract][Full Text] [Related]
10. No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in
Imbert-Bouteille M; Corsini C; Picot MC; Mizrahy L; Akouete S; Huguet H; Thomas F; Geneviève D; Taourel P; Ychou M; Galibert V; Rideau C; Baudry K; Kogut Kubiak T; Coupier I; Hobeika R; Macary Y; Toledano A; Solassol J; Maalouf A; Daures JP; Pujol P
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356116
[TBL] [Abstract][Full Text] [Related]
11. Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
Witjes VM; van Bommel MHD; Ligtenberg MJL; Vos JR; Mourits MJE; Ausems MGEM; de Hullu JA; Bosse T; Hoogerbrugge N
Gynecol Oncol; 2022 Jan; 164(1):221-230. PubMed ID: 34702566
[TBL] [Abstract][Full Text] [Related]
12. Genetic characterization of early onset ovarian carcinoma.
Bernards SS; Norquist BM; Harrell MI; Agnew KJ; Lee MK; Walsh T; Swisher EM
Gynecol Oncol; 2016 Feb; 140(2):221-5. PubMed ID: 26718727
[TBL] [Abstract][Full Text] [Related]
13. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia.
Ben Ayed-Guerfali D; Ben Kridis-Rejab W; Ammous-Boukhris N; Ayadi W; Charfi S; Khanfir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
J Transl Med; 2021 Mar; 19(1):108. PubMed ID: 33726785
[TBL] [Abstract][Full Text] [Related]
14. DrABC: deep learning accurately predicts germline pathogenic mutation status in breast cancer patients based on phenotype data.
Liu J; Zhao H; Zheng Y; Dong L; Zhao S; Huang Y; Huang S; Qian T; Zou J; Liu S; Li J; Yan Z; Li Y; Zhang S; Huang X; Wang W; Li Y; Wang J; Ming Y; Li X; Xing Z; Qin L; Zhao Z; Jia Z; Li J; Liu G; Zhang M; Feng K; Wu J; Zhang J; Yang Y; Wu Z; Liu Z; Ying J; Wang X; Su J; Wang X; Wu N
Genome Med; 2022 Feb; 14(1):21. PubMed ID: 35209950
[TBL] [Abstract][Full Text] [Related]
15. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
[TBL] [Abstract][Full Text] [Related]
16. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
[TBL] [Abstract][Full Text] [Related]
17. Correlation between the risk of ovarian cancer and BRCA recurrent pathogenic variants in Japan.
Sekine M; Enomoto T; Arai M; Yokoyama S; Nomura H; Nishino K; Ikeuchi T; Kuriyama Y; Nakamura S;
J Hum Genet; 2022 May; 67(5):267-272. PubMed ID: 34983974
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of Pathogenic Germline
Abe A; Imoto I; Tange S; Nishimura M; Iwasa T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741847
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes.
Pietragalla A; Arcieri M; Marchetti C; Scambia G; Fagotti A
Int J Gynecol Cancer; 2020 Nov; 30(11):1803-1810. PubMed ID: 32895312
[TBL] [Abstract][Full Text] [Related]
20. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
